Detection of circulating tumour DNA is associated with inferior outcomes in Ewing sarcoma and osteosarcoma: a report from the Children’s Oncology Group-Reference-Cited by-同舟云学术

Detection of circulating tumour DNA is associated with inferior outcomes in Ewing sarcoma and osteosarcoma: a report from the Children’s Oncology Group

Published:2018-08 Issue:5 Volume:119 Page:615-621
ISSN:0007-0920
Container-title:British Journal of Cancer
language:en
Short-container-title:Br J Cancer

Author:

Shulman David S.,Klega Kelly,Imamovic-Tuco Alma,Clapp Andrea,Nag Anwesha,Thorner Aaron R.,Van Allen Eliezer,Ha Gavin,Lessnick Stephen L.,Gorlick Richard,Janeway Katherine A.,Leavey Patrick J.,Mascarenhas Leo,London Wendy B.,Vo Kieuhoa T.,Stegmaier Kimberly,Hall David,Krailo Mark D.,Barkauskas Donald A.,DuBois Steven G.,Crompton Brian D.

Funder

Dr. Ha has a patent pending related to genomic technologies that is not directly related to this work.

Dr. Stephen Lessnick holds patents relevant to the diagnosis of Ewing sarcoma

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://www.nature.com/articles/s41416-018-0212-9.pdf

Reference37 articles.

1. Grier, H. E. et al. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing’s sarcoma and primitive neuroectodermal tumour of bone. N. Engl. J. Med. 348, 694–701 (2003).

2. Womer, R. B. et al. Randomized controlled trial of interval-compressed chemotherapy for the treatment of localised ewing sarcoma: a report from the children’s oncology group. J. Clin. Oncol. 30, 4148–4154 (2012).